Eagle Asset Management Inc. Has $285,000 Position in Genmab A/S (NASDAQ:GMAB)

Eagle Asset Management Inc. lifted its position in shares of Genmab A/S (NASDAQ:GMAB) by 10.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,356 shares of the company’s stock after purchasing an additional 1,121 shares during the period. Eagle Asset Management Inc.’s holdings in Genmab A/S were worth $285,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Legacy Wealth Asset Management LLC increased its position in Genmab A/S by 1.1% during the third quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after buying an additional 471 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its stake in Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after acquiring an additional 478 shares during the period. Russell Investments Group Ltd. raised its stake in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after acquiring an additional 544 shares during the period. Rhumbline Advisers lifted its holdings in Genmab A/S by 7.1% during the 2nd quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock valued at $470,000 after purchasing an additional 1,236 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in Genmab A/S by 43.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after purchasing an additional 1,413 shares during the period. 7.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GMAB has been the subject of a number of research reports. Morgan Stanley restated an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. Redburn Atlantic began coverage on Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Truist Financial reduced their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Price Performance

Genmab A/S stock opened at $20.79 on Tuesday. The stock’s fifty day moving average price is $23.04 and its two-hundred day moving average price is $25.81. The firm has a market cap of $13.76 billion, a PE ratio of 20.18, a price-to-earnings-growth ratio of 0.64 and a beta of 0.99. Genmab A/S has a one year low of $20.34 and a one year high of $32.88.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period last year, the firm earned $0.47 EPS. Sell-side analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.